Core Viewpoint - Nxera Pharma's GPR52 agonist program for schizophrenia will not be licensed by Boehringer Ingelheim, leading to the reversion of all rights and data back to Nxera [1] Group 1: GPR52 Agonist Program - NXE'149 and other GPR52 agonists were developed using Nxera's NxWave™ structure-based drug design platform to address positive, negative, and cognitive symptoms of schizophrenia [2] - A Phase 1 trial of NXE'149 showed a favorable safety profile with no severe adverse events and demonstrated dose-proportional exposure and a long half-life supporting once-daily dosing [3] - The expression of GPR52 in brain regions linked to various schizophrenia symptoms suggests NXE'149 may treat all three symptom domains, offering a potential new therapeutic option [4] Group 2: Future Plans and Financial Impact - Nxera plans to explore strategic opportunities, including a formal out-licensing process for the GPR52 program in 2026 [5] - The decision by Boehringer Ingelheim does not impact Nxera's consolidated financial results for the current accounting period [5] - CEO Christopher Cargill expressed optimism about the potential of the GPR52 program despite the setback, highlighting the strong scientific and clinical foundations established [6] Group 3: Company Overview - Nxera Pharma is focused on developing specialty medicines to meet unmet medical needs in Japan and globally, leveraging its NxWave™ discovery platform [7][10] - The company has an extensive pipeline of over 30 active programs targeting major unmet needs in areas such as obesity, neurology, and immunology [9] - Nxera employs approximately 400 people across key locations including Tokyo, London, and Basel [10]

Core Viewpoint - Nxera Pharma is undergoing a focused restructuring to concentrate investments on high-value programs and reduce operating expenses, aiming for net sales of ≥JPY50 billion and an operating profit margin of ≥30% by 2030 [1][5] Restructuring Objectives - The restructuring aims to prioritize high-probability, high-return programs and streamline operations to enhance efficiency and accelerate program progression [5][6] - A portfolio review has identified non-priority programs for potential partnership or termination, focusing on next-generation therapies for obesity and metabolic disorders [6][12] Financial Strategy - Nxera plans to reduce cash R&D expenditure by approximately JPY3.5 billion in FY2026 and expects a minimum of JPY1.0 billion in year-on-year savings [6][11] - The company maintains a strong cash position with current cash and liquid investments of JPY30.9 billion, allowing flexibility in executing its strategy [6][11] Leadership Changes - Dr. Patrick Foerch has been appointed as Chief Scientific Officer and President of Nxera Pharma UK, bringing significant experience to enhance R&D focus [5][9] - The executive team will be reduced from ten to seven members by March 2026, and a workforce reduction of approximately 15% will occur across Japan and UK operations [6][11] R&D Focus - Nxera will leverage its NxWave™ platform, utilizing AI technology to enhance drug discovery and development, particularly in GPCR-targeted programs [6][12] - The company has an extensive pipeline of over 30 active programs, with several partnered programs progressing through clinical development [12]

Core Viewpoint - Nxera Pharma Co., Ltd. is undergoing a focused restructuring to concentrate investments on high-value programs and reduce operating expenses, aiming for net sales of ≥JPY50 billion and an operating profit margin of ≥30% by 2030 [1][5] Restructuring Objectives - The restructuring aims to prioritize higher-probability, high-return programs and streamline operations to enhance efficiency and accelerate momentum in clinically and commercially viable programs [5][6] - Nxera plans to reduce cash R&D expenditure by approximately JPY3.5 billion in FY2026 and implement a workforce reduction of about 15% across Japan and UK operations [6][11] R&D Focus and Program Prioritization - The strategic emphasis will be on next-generation therapies for obesity, metabolic, and endocrine disorders, leveraging the NxWave™ platform for differentiated medicines [6][13] - AI technology will be integrated into the NxWave™ platform to enhance drug discovery and decision-making processes [6][7] Leadership Changes - Dr. Patrik Foerch has been appointed as Chief Scientific Officer and President of Nxera Pharma UK, bringing extensive experience in R&D leadership [10][11] - The executive team will be streamlined from ten to seven members by March 2026 [6][11] Financial Position and Cost Management - Nxera maintains a strong cash position with current cash and liquid investments of JPY30.9 billion, allowing flexibility in executing its strategy [6][11] - One-time restructuring charges of approximately JPY500 million will be recognized in FY2025, with expected cost savings of at least JPY1.0 billion in the following year [6][11]